Document Detail

Bucindolol, a beta blocker, decreased ventricular fibrillation and maintained mechanical function in a pig model of acute myocardial ischemia.
MedLine Citation:
PMID:  1353366     Owner:  NLM     Status:  MEDLINE    
Bucindolol is a new beta blocker with marked vasodilatory properties and intrinsic sympathomimetic activity. We tested its potential effect against ventricular fibrillation (VF), in a pig model of acute myocardial ischemia. Bucindolol 6 mg/kg IV was administered in two equally divided doses, the first 30 minutes prior to, and the second 10 minutes after, ligation of the anterior descending coronary artery (CAL) in anesthetized open-chest pigs. Bucindolol decreased the incidence of VF to 1/11 versus 14/16 in the control group (p less than 0.005). Bucindolol also decreased the duration of ventricular tachycardia, 15 +/- 8 seconds versus 104 +/- 32 seconds in the control group (p less than 0.01). Bucindolol maintained LVmaxdP/dt at predrug and pre-CAL values, whereas LVmaxdP/dt was decreased by CAL in the control group. Bucindolol decreased arterial pressure and heart rate. Bucindolol increased blood flow in the peripheral ischemic zone (24.6 +/- 1.8% versus 16.2 +/- 1.7% (percent of pre-CAL value) in controls, p less than 0.002), as well as in the nonischemic zones (periischemic zone: 126.4 +/- 6.1% versus 96.7 +/- 4.8% in the control group, p less than 0.0005; remote nonischemic zone: 126.6 +/- 7.1% versus 87.1 +/- 4.3% of pre-CAL value in the control group, p less than 0.0001). Bucindolol had marked antiarrhythmic effects that were associated with beneficial effects on the mechanical function of the left ventricle and on blood flow to the ischemic myocardium.
C A Muller; L H Opie; C A Pineda; M Peisach
Related Documents :
18242556 - Antiarrhythmic effects of beta3-adrenergic receptor stimulation in a canine model of ve...
19148716 - Ventricular tachycardia inducibility after radiofrequency ablation affects the outcomes...
17940856 - Macroreentrant ventricular tachycardia mimicking focal ventricular tachycardia in a cas...
4061296 - Frequency and significance of induced sustained ventricular tachycardia or fibrillation...
22085926 - Wnt1/βcatenin injury response activates the epicardium and cardiac fibroblasts to prom...
22911956 - Risk factors for premature myocardial infarction: a matched case-control study.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  6     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  1992 Jun 
Date Detail:
Created Date:  1992-09-03     Completed Date:  1992-09-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  233-7     Citation Subset:  IM    
Department of Medicine, Groote Schuur Hospital, South Africa.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / pharmacology*,  therapeutic use
Blood Pressure / drug effects
Coronary Circulation / drug effects*
Coronary Disease / drug therapy*,  physiopathology
Disease Models, Animal
Heart Rate / drug effects
Hemodynamics / drug effects*
Propanolamines / administration & dosage,  pharmacology*,  therapeutic use
Ventricular Fibrillation / drug therapy*,  physiopathology
Ventricular Function, Left / drug effects
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Propanolamines; 70369-47-0/bucindolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Large-scale culture system of human CD4+ helper/killer T cells for the application to adoptive tumou...
Next Document:  Exercise tolerance with nebivolol and atenolol.